| 2024-03-19 09:00 | UU:ORMP | | News Release200 | Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation |
| 2024-02-20 08:30 | UU:ORMP | | News Release200 | Oramed Letter to Shareholders |
| 2023-09-22 11:38 | UU:ORMP | | News Release200 | Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company |
| 2023-09-21 18:11 | UU:ORMP | | News Release200 | Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company |
| 2023-09-21 16:05 | UU:ORMP | | News Release200 | Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. |
| 2023-09-13 09:00 | UU:ORMP | | News Release200 | Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder |
| 2023-08-02 07:45 | UU:ORMP | | News Release200 | Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally |
| 2023-06-20 07:55 | UU:ORMP | | News Release200 | Oramed to Present at the 83rd American Diabetes Association Conference |
| 2023-05-18 07:55 | UU:ORMP | | News Release200 | Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit |
| 2023-05-15 09:05 | UU:ORMP | | News Release200 | Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China |